M&G Plc Raises Stock Position in Amgen Inc. (NASDAQ:AMGN)

M&G Plc boosted its position in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 676.5% in the 3rd quarter, Holdings Channel.com reports. The fund owned 283,017 shares of the medical research company’s stock after purchasing an additional 246,568 shares during the period. M&G Plc’s holdings in Amgen were worth $91,131,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Spinnaker Trust grew its stake in Amgen by 1.6% in the 3rd quarter. Spinnaker Trust now owns 8,311 shares of the medical research company’s stock worth $2,678,000 after buying an additional 127 shares in the last quarter. Consilium Wealth Advisory LLC grew its stake in Amgen by 30.8% in the 3rd quarter. Consilium Wealth Advisory LLC now owns 5,013 shares of the medical research company’s stock worth $1,615,000 after buying an additional 1,179 shares in the last quarter. Gordian Advisors LLC purchased a new position in Amgen in the 3rd quarter worth approximately $269,000. Centennial Wealth Advisory LLC purchased a new position in Amgen in the 3rd quarter worth approximately $407,000. Finally, Radnor Capital Management LLC grew its stake in Amgen by 6.5% in the 3rd quarter. Radnor Capital Management LLC now owns 7,495 shares of the medical research company’s stock worth $2,415,000 after buying an additional 460 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on AMGN. Wells Fargo & Company cut shares of Amgen from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $320.00 to $335.00 in a research note on Wednesday, August 7th. Barclays boosted their price objective on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Sanford C. Bernstein assumed coverage on shares of Amgen in a report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price objective for the company. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $305.00 price objective (down from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $380.00 price objective (up from $375.00) on shares of Amgen in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $333.50.

Get Our Latest Stock Report on Amgen

Amgen Stock Up 0.8 %

Shares of NASDAQ AMGN opened at $321.79 on Thursday. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 12 month low of $260.52 and a 12 month high of $346.85. The firm has a market capitalization of $172.91 billion, a PE ratio of 41.20, a price-to-earnings-growth ratio of 2.81 and a beta of 0.60. The firm has a fifty day simple moving average of $323.96 and a two-hundred day simple moving average of $316.68.

Amgen (NASDAQ:AMGNGet Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. During the same period in the prior year, the business earned $4.96 EPS. The company’s revenue for the quarter was up 23.2% on a year-over-year basis. Equities analysts expect that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a yield of 2.80%. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Articles

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.